Epizyme to Present at the Jefferies 2017 London Healthcare Conference
November 09 2017 - 6:30AM
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical
company creating novel epigenetic therapies, today announced that
management will present a company overview at the Jefferies 2017
London Healthcare Conference on Thursday, Nov. 16, 2017 at 11:20
a.m. GMT. The conference is being held Nov. 15-16, 2017 at the
Waldorf Hilton, Aldwych, London.
To access the live webcast of Epizyme's presentation, please
visit the Events & Presentations page within the Investor page
of the website at www.epizyme.com. A replay of the webcast will be
available on the Epizyme website for 60 days following the
conference.About Epizyme, Inc.Epizyme, Inc. is a
clinical-stage biopharmaceutical company committed to rewriting
cancer treatment through novel epigenetic medicines. Epizyme is
broadly developing its lead product candidate, tazemetostat, a
first-in-class EZH2 inhibitor, with studies underway in both solid
tumors and hematological malignancies, as a monotherapy and
combination therapy in relapsed and front-line disease. Using the
Company's proprietary platform, Epizyme has pioneered the
identification and development of small molecule inhibitors of
chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are
part of the system of gene regulation, referred to as epigenetics,
that controls gene expression. Genetic alterations can result in
changes to the activity of CMPs, which can allow cancer cells to
grow and proliferate. By focusing on the genetic drivers of
cancers, Epizyme's science seeks to match targeted medicines with
the specific patients that need it. For more information, visit
www.epizyme.com.
Contacts:Cheya Pope, Epizyme,
Inc.media@epizyme.com617-229-7561
Monique Allaire, THRUST IRmonique@thrustir.com617-895-9511
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2024 to May 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From May 2023 to May 2024